PharmaTher Announces Grant of U.S. Patent on Ketamine Formulation
16 févr. 2022 07h00 HE
|
PharmaTher Holdings Ltd.
TORONTO, Feb. 16, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, is pleased to announce...
PharmaTher Granted FDA Orphan Drug Designation for Ketamine to Treat Status Epilepticus
01 févr. 2022 07h00 HE
|
PharmaTher Holdings Ltd.
TORONTO, Feb. 01, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, is pleased to announce...
PharmaTher Announces FDA Approval of Investigational New Drug (IND) Application for Ketamine to Treat ALS
12 janv. 2022 07h00 HE
|
PharmaTher Holdings Ltd.
TORONTO, Jan. 12, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a company focused on the development and commercialization of...
PharmaTher Announces Publication of Research Data for KETABET™
04 janv. 2022 07h00 HE
|
PharmaTher Holdings Ltd.
Second published study to demonstrate the potential therapeutic utility and mechanism of action of KETABET™ (patented combination of ketamine and betaine) in models of depression Repeated use of...
PharmaTher Provides Update on Product Pipeline and Expected Milestones for 2022
21 déc. 2021 07h00 HE
|
PharmaTher Holdings Ltd.
Focused on becoming a leader in the development and commercialization of specialty ketamine prescription-based products Expected milestones for 2022 include initiating Phase 3 clinical study for...
PharmaTher Enters Into Process Development Agreement With LTS LOHMANN for Ketamine Microneedle Patch
20 déc. 2021 07h00 HE
|
PharmaTher Holdings Ltd.
TORONTO and ANDERNACH, Germany, Dec. 20, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (“PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a company focused on the development and commercialization of...
PharmaTher Announces Positive Research Results for LSD Microneedle Patch
14 déc. 2021 07h00 HE
|
PharmaTher Holdings Ltd.
Delivering LSD via microneedle patch unlocks potential for desired dosage forms and pharmacokinetic profiles for improved safety and effectivenessPursuing Phase 2 clinical studies in 2022 with LSD and...
PharmaTher Granted New Japanese Patent for KETABET™ (Ketamine Combination Formulation), Strengthening Global Patent Portfolio
30 nov. 2021 07h00 HE
|
PharmaTher Holdings Ltd.
TORONTO, Nov. 30, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to announce...
PharmaTher Applies for FDA Orphan Drug Designation for Ketamine to Treat Rare Neurological Disorder Status Epilepticus
24 nov. 2021 07h30 HE
|
PharmaTher Holdings Ltd.
Adds to PharmaTher’s existing FDA orphan drug portfolio with amyotrophic lateral sclerosis and complex regional pain syndromeStrengthens commitment to treat rare disorders and life-threatening...
PharmaTher Announces Positive Research Results for Psilocybin Microneedle Patch
11 nov. 2021 07h59 HE
|
PharmaTher Holdings Ltd.
Delivering psilocybin via microneedle patch unlocks potential for desired dosage forms and pharmacokinetic profiles for improved safety and effectiveness.Completing microneedle patch research programs...